Alexis Ji is a partner at Illumina Ventures. She brings 12 years of experience in research, product development, and venture investment in pharmaceuticals and genomics. Alexis focuses her investment on early-stage technology platforms and applications in tools, diagnostics, therapeutics, and digital health.
Prior to Illumina Ventures, Alexis worked at WuXi Apptec Corporate Fund and then WuXi Healthcare Ventures, a US-China cross-border life science VC firm, focused on investment opportunities in therapeutics and medtech in the US. Alexis was instrumental in the investment of Twist Bioscience, 23andme, Juno Therapeutics (JUNO), Unity Biotechnology, Vivace Therapeutics, Medeor Therapeutics, Lumo Bodytech, and Ideaya Therapeutics, etc. Before joining WuXi, Alexis worked at ARCH Venture Partners where she focused on evaluation of early-stage life science and physical science opportunities and was involved in the founding of Twist Bioscience and investment in Nextcode Health.
Alexis started his career as a senior scientist at Merck where she worked on early drug discovery exploiting system biology approaches, and at Roche where she focused on translational research and clinical trial analysis in virology. At Life Technologies, her expertise was on molecular diagnostics assay development and comparative genomics based on next-generation sequencing.
Alexis holds a PhD in Molecular Genetics from Washington University in St. Louis, where she focused her thesis on non-coding RNA discovery. She holds an MBA from University of Chicago Booth School of Business, a Masters in Molecular Biology and Structural Biology from Chinese Academy of Sciences, Institute of Biophysics, and a Bachelor in Biochemistry from Shandong University.